Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2006-09-05
2006-09-05
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S728000, C514S866000, C514S685000
Reexamination Certificate
active
07101910
ABSTRACT:
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
REFERENCES:
patent: 4011321 (1977-03-01), Coates et al.
patent: 4098816 (1978-07-01), Thorne et al.
patent: 4638094 (1987-01-01), Nakai et al.
patent: 4845231 (1989-07-01), Kees
patent: 5817693 (1998-10-01), Cousins et al.
patent: 5948803 (1999-09-01), Maeda et al.
patent: 6555536 (2003-04-01), Burris et al.
patent: 9802163 (2000-11-01), None
patent: 1929165 (1969-12-01), None
patent: 2 309 986 (1974-08-01), None
patent: 2459468 (1975-07-01), None
patent: 2512673 (1975-10-01), None
patent: 2527066 (1976-01-01), None
patent: 3012012 (1981-10-01), None
patent: 71399 (1983-02-01), None
patent: 288190 (1988-10-01), None
patent: 393400 (1990-10-01), None
patent: 407891 (1991-01-01), None
patent: 2191887 (1974-02-01), None
patent: 1488330 (1977-10-01), None
patent: 47025149 (1972-10-01), None
patent: 50014653 (1975-02-01), None
patent: 52025734 (1977-02-01), None
patent: 55015460 (1980-02-01), None
patent: 56115747 (1981-09-01), None
patent: 61040270 (1986-02-01), None
patent: 01063570 (1989-03-01), None
patent: 01/181281 (1989-07-01), None
patent: 04159266 (1992-06-01), None
patent: 10130241 (1998-05-01), None
patent: WO 88/08418 (1988-11-01), None
patent: 9212123 (1992-07-01), None
patent: 9219123 (1992-07-01), None
patent: WO 93/08799 (1993-05-01), None
patent: WO 94/27993 (1994-12-01), None
patent: WO 95/13262 (1995-05-01), None
patent: WO 97/30017 (1997-08-01), None
patent: WO 98/07681 (1998-02-01), None
patent: 9807691 (1998-02-01), None
patent: WO 98/08836 (1998-03-01), None
patent: WO 98/25608 (1998-06-01), None
patent: WO 99/11255 (1999-03-01), None
patent: WO 99/20275 (1999-04-01), None
patent: WO 99/62520 (1999-12-01), None
patent: 9962520 (1999-12-01), None
patent: WO 00/23409 (2000-04-01), None
patent: WO 00/63161 (2000-10-01), None
patent: WO 01/40170 (2001-06-01), None
patent: WO 01/81340 (2001-11-01), None
patent: WO 02/02119 (2002-01-01), None
patent: WO 02/14291 (2002-02-01), None
patent: WO 02/059077 (2002-08-01), None
patent: 6705655 (1968-02-01), None
Chemical Abstract DN 113:115839, also cited as Syn thetic Communications 20/5, 773-81(1990).
Chemical Abstract DN 132:22755, also cited as WO9962520).
Chemical Abstract DN 126:74645, also cited as J. Chem. Soc., Parkins Transactions 1,Org. & Bio-Org. Chem.,21,2603-2613(1996).
Chemical Abstract DN 117:251790, also cited as WO 9212123).
Chemical Abstract DN 113:115839, also cited as Synthetic communications,20/5,773-81(1990).
Chemical Abstract DN 99: 122287,also cited as EP 71399.
Kawamatsu et al(Arzneim. Forsh.,vol. 30 ISS3,454-459(1980).
Witiak, et al., “Synthesis of Ethyl 6-Substituted-Chroman-and-Chromone-2-carboxylates. A Comparative Structure-Activity Study Employing the 6-Phenyl and Phenoxy Analogs in the Triton Hyperlipidemic Rat Model”, Journal Medical Chemistry, vol. 18, No. 9, pp. 934-942, 1975.
Kawamatsu, et al., Studies on antihyperlipidemic agents. Part 1, Synthesis and hypolipidemic activities of phenoxyphenylalkanoic acid derivatives, Arzneim. Forsch, vol. 30, Issue 3, pp. 445-459, 1980. (Abstract).
Liu, et al., “The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes”, Endocrinology, vol. 139, No. 11, pp. 4531-4539, (1998).
Kees, et al., “Perfluoro-N-[4-(1 H-tetrazol-5-ylmethyl) Phenyl]-alkanamides. A New Class of Oral Antidiabetic Agents”, Journal of Medicinal Chemistry, vol. 32, pp. 11-13, (1989).
Shinkai, et al. “4-(trans-4-Methylcyclohexyl)-4 Oxobutyric Acid (JTT-608). A New Class of Antidiabetic Agent”, Journal of Medicinal Chemistry, vol. 41, No. 27, pp. 5420-5428, (1998).
Abstract 560-P, Hodge, et al. “PN2022: Antidiabetic Efficacy and Reversal of Stealohepatitis in ob/ob Mice”, Diabetes, Abstract Book 62nd Scientific Sessions, vol. 51 Suppl. 2, p. A139, Jun. 2002.
Abstract 561-P, Hodge, et al., “PN2034: Orally Active Antidiabetic Agent with a Unique Spectrum of of Activity and Enhanced Safety Profile”, Diabetes, Abstract Book 62nd Scientific Sessions, vol. 51 Suppl. 2, p. A139, Jun. 2002.
Abstract 568-P, Lu, et al., “A Novel Antidiabetic Agent That Is a Selective PPAR Modulator”, Diabetes, Abstract Book 62nd Scientific Sessions, vol. 51, Suppl. 2., p. A141, Jun. 2002.
Abstract 586-P, von Borstel, et al. “PN2034: Reversal of Insulin Resistance and Attenuation of Weight Gain in Mice on a High-Fat Diet”, Diabetes, Abstract Book 62nd Scientific Sessions, vol. 51, Suppl. 2, p. A145, Jun. 2002.
Poster #560, Hodge, et al., “PN2022: Antidiabetic Efficacy and Reversal of Steatohepatitis in ob/ob Mice.” Presentation at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on Jun. 14-18, 2002 and corresponding to Abstract 560-P.
Poster #561, Hodge, et al., “PN2034: Orally Active Antidiabetic Agent with a Unique Spectrum of Activity and Enhanced Safety Profile”, Presentation given at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on Jun. 14-18, 2002 and corresponding to Abstract 560-P.
Poster #568, Lu, et al., “PN2034-A Novel Antidiabetic Agent That Is a Selective PPAR Modulator”, Presentation given at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on Jun. 14-18, 2002 and corresponding to Abstract 568-P.
Poster #586, von Borstel, et al., “PN2034: Reversal of Insulin Resistance and Attenuation of Weight Gain in Mice on a High-Fat Diet”, Presentation given at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on Jun. 14-18, 2002 and corresponding to Abstract 586-P.
Karche, et al., “Electronic Effects in Migratory Groups . . . ”, Journal of Organic Chemistry, vol. 66, No. 19, pp. 6323-6332, 2001. (Abstract).
Poupardin, et al.,“First approach to the cycloisodityrosine unit of RA-IV”, Tetrahedron Letters, vol. 42, No. 8, pp. 1523-1526, 2001. (Abstract).
Manthey, et al., “Synthesis of Human Ultraviolet Filter Compounds: . . . ”, Journal of Organic Chemistry, vol. 64, No. 11, pp. 3930-3933, 1999. (Abstract).
Wu, et al., “Improvement on the preparation of .beta.-keto esters”, Huaxue Shiji, vol. 20, No. 6, pp. 376-377, 1998. (Abstract).
Wu, et al., “Total syntheses of furogualacin and related analogs”, Huaxue Yanjiu Yu Yingyoung, vol. 9, No. 6, pp. 595-599, 1997. (Abstract).
Fadnavis, et al., “Baker's yeast mediated enantiospecific synthesis of anti-(2R,3R). . . ”, Tetrahedron: Asymmetry, vol. 8, No. 24, pp. 4003-4006, 1997. (Abstract).
Wu, et al., “A modification of the Knorr oxidative coupling method for preparation of 1,4-diketones”, Synthetic Communications, vol. 27, No. 2, pp. 331-336, 1997. (Abstract).
Girard, et al. “Syntheses of the syn and anti .alpha .-amino-.beta.-hydroxy acid of vancomycin: . . . ”, Tetrahedron Letters, vol. 37, No. 44, pp. 7967-7970, 1996. (Abstract).
Smith, et al., “Synthesis and PAF antagonist activity of some 2,5-diaryltetrahydrofurans incorporating PAF-like functional groups”, European Journal of Medicinal Chemistry, vol. 31, No. 5, pp. 347-358, 1996. (Abstract).
Maruyama, et al., “A synthesis of (.+−.)-pinoresinol and its related compound using potassium persulfate (K2S208) oxidation of benzoylacetates”, Heterocycles, vol. 37, No. 2, pp. 839-845, 1994. (Abstract).
Rao, et al., “Studies on cyclodepsipeptides. Part II. The total synthesis of jaspamide and geodiamolide-D”, Tetrahedron Letters, vol. 34, No. 44, pp. 7085-7088, 1993. (Abstract).
Colotta, et al., “Tricyclic heteroaromatic systems . . . ”, Farmaco, vol. 46, No. 10, pp. 1139-1154, 1991. (Abstract).
Dillard, et al., “(Phenylmethoxy) phenyl derivatives of w-oxo- and w-tetrazolylalkanoic acids . . . ”, J. Med
Sharma Shalini
von Borstel Reid W.
Kreisler Lewis J.
Patel Sudhaker B.
Raymond Richard L.
Wellstat Therapeutics Corporation
LandOfFree
Compounds for the treatment of metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of metabolic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3555938